A Phase 2 interventional study of Cerebrolysin (Nerve growth factor) in Cerebral Palsy Children, Children With Traumatic Brain Injury and Mental Handicap, sponsored by Ain Shams University. Status unknown at 1 site in Egypt. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2014-04-16.
Sponsored by Ain Shams University · Phase 2, Interventional, and Treatment
Cerebral palsy (CP) is the most frequent cause of motor handicap among children. The economic burden of CP in USA includes $1.18 billion in direct medical costs, $1.05 billion in direct non-medical costs, and an additional $9.24 billion in indirect costs, for a total cost of $11.5 billion or $921,000 average cost per person. Associated disabilities as mental retardation, delayed speech development add psychological burden of the disease on the family as well as economic burden.
Mental retardation is the major problem in children with cerebral palsy. Improving mental development will have a positive effect on quality of life for the child and his family. Treating associated impairments (mental retardation) with Cerebrolysin will improve mental development and quality of life, and will decrease the economic burden in children with cerebral palsy.
2,113 studies on the registry are indexed under Brain Injuries; 384 are open to participants now.
This study's planned enrollment of 100 is above the median of 48 across 1,331 interventional studies indexed under Brain Injuries.
Browse Brain Injuries studies →Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Nerve growth factor Cerebrolysin will be given to the intervention group
Drug: Cerebrolysin (Nerve growth factor)
These children will receive conventional treatment for cerebral palsy
Cerebrolysin will be given to the intervention group
Also known as: Cerebrolysin
neurodevelopment
Intelligence quotient (IQ) assessment at base line and after 3 and 6 month of therapy
Time frame: 6 months
This study is status unknown, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams University